Replimune Group, Inc. (REPL)
13.07
-0.35
(-2.61%)
USD |
NASDAQ |
Oct 12, 16:00
13.04
-0.03
(-0.23%)
After-Hours: 07:49
Replimune Group EPS Diluted (Quarterly) : -0.7202 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.7202 |
| March 31, 2026 | -0.8852 |
| December 31, 2025 | -0.7694 |
| September 30, 2025 | -0.9041 |
| June 30, 2025 | -0.9473 |
| March 31, 2025 | -0.9617 |
| December 31, 2024 | -0.7945 |
| September 30, 2024 | -0.6753 |
| June 30, 2024 | -0.7772 |
| March 31, 2024 | -0.8968 |
| December 31, 2023 | -0.767 |
| September 30, 2023 | -0.9018 |
| June 30, 2023 | -0.7467 |
| March 31, 2023 | -0.8688 |
| December 31, 2022 | -0.686 |
| September 30, 2022 | -0.787 |
| June 30, 2022 | -0.7794 |
| March 31, 2022 | -0.6696 |
| December 31, 2021 | -0.5672 |
| Date | Value |
|---|---|
| September 30, 2021 | -0.5636 |
| June 30, 2021 | -0.5261 |
| March 31, 2021 | -0.4617 |
| December 31, 2020 | -0.4411 |
| September 30, 2020 | -0.4565 |
| June 30, 2020 | -0.4388 |
| March 31, 2020 | -0.4306 |
| December 31, 2019 | -0.4642 |
| September 30, 2019 | -0.3517 |
| June 30, 2019 | -0.3003 |
| March 31, 2019 | -0.2102 |
| December 31, 2018 | -0.243 |
| September 30, 2018 | -0.2629 |
| June 30, 2018 | -0.3154 |
| March 31, 2018 | -0.215 |
| December 31, 2017 | -0.1367 |
| September 30, 2017 | -0.1463 |
| June 30, 2017 | -0.1116 |
| March 31, 2017 | -0.1214 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Kalaris Therapeutics, Inc. | -0.4839 |
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.0464 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -69.77M |
| Total Expenses (Quarterly) | 69.77M |
| Enterprise Value | 1.014B |
| Earnings Yield | -25.09% |
| Normalized Earnings Yield | -25.09 |